Online Mindfulness Intervention for Emotional Distress (MIED) in Adults With Emotional Eating
NCT07933978, Not applicable, Not yet recruiting, Xinghua Liu
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Online Mindfulness Intervention for Emotional Distress (MIED) in Adults With Emotional Eating | ClinicalTrials.gov |
| NCT number | NCT07933978 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 108 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Xinghua Liu | ClinicalTrials.gov |
| Conditions | Emotional Eating, Emotional Distress | ClinicalTrials.gov |
| Interventions | Mindfulness Intervention for Emotional Distress | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Chinese 11-Item DEBQ Emotional Eating Subscale | Baseline, 2 and 4 weeks after scheduled MIED program start, at the end of the 8-week MIED program (after the eighth scheduled session), and 1 month after scheduled program completion. Both groups follow the same schedule. | Self-reported emotional eating will be assessed using the Chinese 11-item emotional eating subscale of the Dutch Eating Behavior Questionnaire (DEBQ-EE). Items are rated from 1 (lowest frequency) to 5 (highest frequency), using the validated Chinese response wording. The outcome score is the mean of the 11 item scores, ranging from 1 to 5; higher scores indicate more frequent negative emotion-related urges or tendencies to eat. | ClinicalTrials.gov |
| Secondary | Overall Anxiety Severity and Impairment Scale (OASIS) | Baseline, 2 and 4 weeks after scheduled MIED program start, at the end of the 8-week MIED program (after the eighth scheduled session), and 1 month after scheduled program completion. Both groups follow the same schedule. | The OASIS is a 5-item self-report measure designed to assess the frequency and severity of anxiety symptoms, as well as the extent of anxiety-related functional impairment and avoidance, over the past week. Each item is rated on a 5-point scale from 0 to 4, with total scores ranging from 0 to 20. Higher scores indicate greater overall anxiety severity and impairment. The OASIS has demonstrated good reliability and validity in both clinical and nonclinical samples (Norman et al., 2006). | ClinicalTrials.gov |
| Secondary | Overall Depression Severity and Impairment Scale (ODSIS) | Baseline, 2 and 4 weeks after scheduled MIED program start, at the end of the 8-week MIED program (after the eighth scheduled session), and 1 month after scheduled program completion. Both groups follow the same schedule. | The ODSIS is a 5-item self-report measure designed to assess the frequency and severity of depressive symptoms, as well as depression-related functional impairment and avoidance, over the past week. Each item is rated on a 5-point scale from 0 to 4, with total scores ranging from 0 to 20. Higher scores indicate greater overall depression severity and impairment. The ODSIS has demonstrated good reliability and validity in both clinical and nonclinical samples (Bentley et al., 2014). | ClinicalTrials.gov |
| Other | Chinese Short Form of the Five Facet Mindfulness Questionnaire | Baseline, 2 and 4 weeks after scheduled MIED program start, at the end of the 8-week MIED program (after the eighth scheduled session), and 1 month after scheduled program completion. Both groups follow the same schedule. | Mindfulness will be assessed using the Chinese 20-item short form of the Five Facet Mindfulness Questionnaire (FFMQ-SF). | ClinicalTrials.gov |
| Other | Attendance at Online MIED Group Sessions | Attendance is recorded at each of the 8 scheduled online MIED group sessions. Sessions are held once weekly at a fixed time over 8 weeks, and each session lasts 120 minutes. | Attendance will be summarized as the number of online MIED group sessions attended by each participant assigned to the intervention group | ClinicalTrials.gov |
| Other | Days of Digital Practice Recorded by the iMIED Platform | Daily from Day 1 through Day 49 of the iMIED mini-program. Day 1 is the scheduled start date of the mini-program. | Digital practice participation will be summarized as the number of days with a recorded practice activity during the 49-day iMIED program | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)